CCRM
Tanvi Doshi Arora, PhD, is an experienced professional in the biopharmaceutical field with a strong background in mammalian cell culture process development and molecular biology. Currently serving as an MSAT at CCRM since May 2021, previous roles include Senior Research Scientist and Research Scientist at Intas Pharmaceuticals Ltd., and Research Executive at Ipca Laboratories Limited, focusing on monoclonal antibodies and clone development. Tanvi's academic journey culminated in a PhD in Biochemistry and Molecular Biology from the National Institute for Research in Reproductive Health, where research centered on epigenetic changes linked to environmental endocrine disruptors. Additional qualifications include a Master's Degree in Biotechnology from the University of Mumbai and a research fellowship in Biochemistry.
This person is not in any teams
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.